This disorder affects both men and women. It can occur at any age but usually is diagnosed in people between 50 and 70 years old. Only about three people out of every 200,000 will develop this disease, which comes in several different forms.
Is It Cancer?
A lot of websites refer to myelofibrosis as “a rare blood cancer.” That’s a simple way to sum it up, but it’s not technically correct.
Myelofibrosis is classified as a myeloproliferative neoplasm, which is a group of disorders that all include overproduction of at least one type of blood cell. These conditions have some similarities to cancer, but are not necessarily cancerous. The growths they cause can be benign (noncancerous), malignant (cancerous), or precancerous.
Myelofibrosis can increase your risk of some blood cancers, and it can also be caused by blood cancers.
Symptoms
As many as 25% of people with myelofibrosis have no symptoms.
Those who do have symptoms may experience:
An enlarged spleen, which causes discomfort in the upper-left abdomen or pain in the upper-left shoulderAnemia, which can lead to fatigue and weaknessShortness of breathFeverWeight lossNight sweatsUnexplained bleedingBleeding and clotting problems due to the impact on blood platelets
How Is the Spleen Involved?
The spleen becomes involved because your body is trying to produce red blood cells wherever it can, which isn’t supposed to happen.
Before babies are born, their bodies can produce new blood cells in the bone marrow, spleen, liver, and lymph nodes. Around the time of birth, though, blood-cell production becomes solely a function of bone marrow.
Dysfunction of the bone marrow causes your body to revert back to producing red blood cells in other locations, which can put a strain on those organs.
Complications
Some of the more serious complications of myelofibrosis may include:
Tumors made of developing blood cells forming outside the bone marrow Slowed blood flow to the liver, leading to a condition called portal hypertension Distended veins in the esophagus, known as esophageal varices, which may rupture and bleed
Causes
Myelofibrosis can be primary or secondary. Primary means that it wasn’t caused by another illness, while secondary means that it was.
Primary Myelofibrosis
Experts aren’t yet sure what causes primary, or idiopathic, myelofibrosis. They’ve linked several genes and types of marrow cells to the condition, including a genetic mutation called the JAK2 V617F missense mutation.
However, researchers don’t know what causes the mutation, and not everyone with this mutation will develop the disease.
Secondary Myelofibrosis
Secondary myelofibrosis can be caused by:
Blood cancers Other myeloproliferative neoplasms, including polycythemia vera and essential thrombocythemia Chemical injury Physical injury Bone marrow infection Loss of blood supply to the bone marrow
While the disease is called simply myelofibrosis regardless of the cause, researchers believe there’s still much to learn about the differences between each type.
Diagnosis
Your healthcare provider may begin to suspect myelofibrosis due to your symptoms and/or a physical exam.
They can then order several tests to aid in the diagnosis, including:
Blood counts Other blood work Imaging tests such as X-rays and MRI Bone marrow biopsy Genetic tests
They may also test you for other conditions that can look like myelofibrosis, such as:
Chronic myelogenous leukemia Other myeloproliferative syndromes Chronic myelomonocytic leukemia Acute myeloid leukemia
Treatment
Right now, there’s no drug that cures myelofibrosis. Treatments are intended to relieve symptoms and prevent complications, improve blood cell counts, and, if necessary, reduce an enlarged spleen.
Treatment is guided by:
Whether or not you’re symptomaticThe risks involved with your specific caseYour age and overall health
If you don’t have symptoms and are at low risk for complications, you may just need observation.
The drug Jakafi (ruxolitinib) is approved by the Food and Drug Administration (FDA) for treating intermediate and high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.
In February 2022, the FDA approved Vonjo (pacritinib) to treat intermediate or high-risk primary or secondary myelofibrosis in adults with platelet levels below 50,000/µL. Other drugs that can be used include Inrebic (fedratinib) and Hydrea (hydroxyurea).
For high-risk cases, healthcare providers sometimes consider transplanting stem cells from a donor, but this comes with some risks, and not everyone is eligible.
Enlarged Spleen
Treatments for an enlarged spleen include:
Medications, including Jakafi and VonjoChemotherapyLow-dose radiation therapyBone marrow (stem cell) transplantationSplenectomy (surgical removal of the spleen)
Anemia
If anemia is a problem for you, it may be treated with:
Iron supplementsFolate supplementsBlood transfusionsMedications, including bone-marrow stimulators, androgens, and immunomodulators
Prognosis
On average, individuals with myelofibrosis survive for five years after diagnosis. About 20% of individuals with the disorder survive 10 years or more.
The people with the best prognosis are those with hemoglobin levels above 10 g/dL, platelet counts above 100,000/uL, and those with less liver enlargement.
A Word From Verywell
The prognosis for someone with myelofibrosis may sound dire, but keep in mind that those numbers are historical. The outlook is continuously improving as new treatments are developed and researchers learn more about the disorder. Talk to your healthcare provider about what you can do to treat your illness, take care of yourself, and increase your odds of beating this disease.
